We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

DYMIND BIOTECHNOLOGY

Dymind designs, manufactures and sells a range of auto hematology analyzers and home ventilator. The company also off... read more Featured Products: More products

Download Mobile App




AI-Powered Automatic Hematology Analyzer with RET Advances Diagnostic Capabilities of Laboratories

By LabMedica International staff writers
Posted on 12 May 2023
Print article
Image: The DH-615 AI automatic hematology analyzer with RET (Photo courtesy of Dymind)
Image: The DH-615 AI automatic hematology analyzer with RET (Photo courtesy of Dymind)

Currently, hematology analyzers can measure various parameters, although most instruments can only provide simple information. When doctors are faced with a large amount of data but do not have enough time to analyze and process it, they can experience information confusion and overload. As the amount of information generated by hematology analyzers increases, clinicians can be affected by excessive workload, resulting in overlooking of critical information. Now, a cutting-edge hematology analyzer applies artificial intelligence (AI) analysis to generate truly interpretable information which helps decrease turn-around time, minimize technical misclassifications and reduce the workload of clinicians.

The new DH-615 hematology analyzer from Dymind Biotechnology Co., Ltd. (Shenzhen, China) based on fluorescent nucleic acid staining technology and the company’s proprietary AI Cube technology combines 6-DIFF with RET, greatly improving identification of abnormal cells and enhancing the ability to analyze hematological diseases such as leukemia, anemia, etc. In comparison to the traditional flag alarm functions, AI Cube technology provides more comprehensive information which is truly interpretable for the analysis of diseases, rather than simply providing conclusive data. Using Al technology, the DH-615 provides the graphics of the normal group and the corresponding diseases of different degrees for the reference of clinicians, which is more intuitive and clear. The DH-615 hematology analyzer perfectly combines AI analysis technology and DMS (Data Management System) for technical integration and higher compatibility.

As one of the most common laboratory tests for anemia diagnosis, blood routine examination has an important initial screening significance for further diagnosis of anemia. Some of the key indicators associated with anemia in blood routine are RBC counting, HGB concentration, MCV, and Reticulocytes (RET). The DH-615 is the first cutting-edge hematology analyzer with RET, which improves efficiency and accuracy for clinical detection in anemia and other diseases. Using nucleic acid fluorescence staining technology, DH-615 can summarize the four types of RET into three parameters according to the different nucleic acid content in different types of RET (different fluorescence intensity), which are HFR (High Fluorescent Ratio), MFR (Middle Fluorescent Ratio) and LFR (Low Fluorescent Ratio). The detection of reticulocytes enhances testing for bone marrow erythropoiesis and related diseases.

In addition, the DH-615 supports automated sampling of venous and capillary whole blood, which reduces the pressure of blood collection while increasing the detection velocity and reducing the risk of biological contamination. With the function of automated capillary blood sampling, it completely solves the pain points of the complicated operation process in the laboratory. The DH615 series adopts self-developed software to achieve full-process management, which provides accurate and fast test results for the outpatient and emergency laboratory without manual operation.

Related Links:
Dymind Biotechnology Co., Ltd. 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Pathology

view channel
Image: Comparison of traditional histopathology imaging vs. PARS raw data (Photo courtesy of University of Waterloo)

AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis

The process of biopsy is important for confirming the presence of cancer. In the conventional histopathology technique, tissue is excised, sliced, stained, mounted on slides, and examined under a microscope... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.